Live data from Hacker News

Oxford University breakthrough on global COVID-19 vaccine

ox.ac.uk

151–160 of 569 posts

Re: Oxford University breakthrough on global COVID-19 vaccine

#151
post #10

I think I read (and I may be wrong) that the costs for the vaccines per dose were roughly as follows: Moderna: £45, Pfizer: £20, Oxford: £3, The Oxford one is also easier to store and transport.

Yes, the Oxford/AstraZeneca vaccine is much cheaper: https://www.bloomberg.com/news/articles/2020-11-22/astra-oxf...

Re: Oxford University breakthrough on global COVID-19 vaccine

#152
post #20

Earlier quoted context omitted.

Google claims that the smallpox vaccine was somewhere between 90-97% effective (they didnt do fully controlled studies back in the day) Keep in mind, that controlling covid is a giant win. We don't need to eradicate it, just get things under control.

> We don't need to eradicate it, just get things under control Based on what we've seen there is no grey area. Either you fully control it which then ends up basically eradicating it e.g. Australia/NZ or you don't and then you end up like EU/US and going in and out of infection waves.

Absence of evidence does not imply evidence of absence.

Anything that reduces the R rate sufficiently will mean fewer outbreaks and reduce the strain on the hospital system.

Re: Oxford University breakthrough on global COVID-19 vaccine

#153

While we now get the results from various COVID-19 vaccines I see a societal issue brewing up. How will we deal with the perceived uncertainty of the safety of these vaccines and the surrounding (dis-)infodemic? I read recently that in some European country (was it Germany?) the willingness to vaccinate against COVID-19 went down from 80% to 60%. With these numbers policy makers will have a hard time convincing the b…

If even one gets sick after taking vaccine the media will jump on it and focus on nothing else for days / weeks.

I think getting people vaccinated is going to be a huge challenge.

Re: Oxford University breakthrough on global COVID-19 vaccine

#154

Earlier quoted context omitted.

This vaccine is an inactive host virus whose payload has been replaced by the coronavirus "spike". It has always been a worry that the body will generate immunity to the host virus and thus make the vaccine less effective. That is a likely explanation for the first-full-dose regimen being less effective.

Shouldn't it warrant a research if even smaller dose has even higher efficiency?

Yes. But clinical trials are expensive ($100m plus) and time consuming.

Re: Oxford University breakthrough on global COVID-19 vaccine

#155
post #57

Title is misleading. They tested few configurations, we should use the most optimal one, not the average. Much better source: https://www.astrazeneca.com/media-centre/press-releases/2020... Good: + likely 90% effective if we use optimal dosing + no significant side effective. Looks better than Pfizer or Moderna. + already pre-produced at huge scale, 3 Bln doses in 2021 + easy to store and administer, just regular fri…

Interesting its cheaper than mRNA, i thought that was one of the benefits of using mRNA, was that it was supposed to be cheaper to manufacture.

One big difference is that RNA is more generic. Within certain parameters it doesn't matter which specific RNA sequence you produce, it always works the same way and you can use the same facilities for this. There are potential cost advantages there, if you can use a generic, validated process to produce different types of vaccines or drugs without having to develop, tune and certify the core production from scratch every time.

I don't know the economics here, but I would assume that cost advantages are much more likely to appear for small-scale products here than what we have now, producing a billion doses in large factories.

Re: Oxford University breakthrough on global COVID-19 vaccine

#157
post #5

The key differentiator here is the storage requirements (2-8c ‘normal refrigerator’). That’s much more accessible to developing / low GDP countries as opposed the cumbersome and expensive storage requirements of the other two.

Moderna vaccine also seems to have similar storage requirements with a high price tag. BioNTech otoh has impractical storage requirements for the third world. AstraZenca's price and storage combiation may open possibilities for distributing this globally.

Re: Oxford University breakthrough on global COVID-19 vaccine

#158

Earlier quoted context omitted.

[flagged]

I don't see why they shouldn't be able to make a fair profit.

I don’t see why it’s any different to war profiteering. Legal, yes - moral, debatable.

Re: Oxford University breakthrough on global COVID-19 vaccine

#159
post #84
post #65

Earlier quoted context omitted.

I dont think its true that smallpox is 100% effective

It isn't. It is comparable to the measles vaccine. Smallpox has a lot lower R-value which means the vaccine is very good at preventing outbreaks. A vaccinated individual will also have milder symptoms. Together with how rare adverse reactions are to the vaccination, the smallpox vaccine is really a wonder.

That’s not really true about smallpox - it’s R is somewhere between 5-8, SARS-CoV-2 is about 2.5.

Higher R0 means you need a greater percentage vaccinated population to achieve herd immunity

Re: Oxford University breakthrough on global COVID-19 vaccine

#160
post #62

Earlier quoted context omitted.

Maybe for less developed countries, but i think for major economies, the price difference is insignificant relative to the benefits of any vaccine.

If they actually get to 90% or more, why would anyone bother with the more expensive and cumbersome vaccines? Except that the EU already signed a deal to buy the vaccines from AstraZeneca, Sanofi and Johnson & Johnson.

Because even with all 3 vaccines we still don't have the supply needed to vaccinate everyone immediately.
Post reply on HN